FDA Tightens Accelerated Approval Pathway, Rejects Regenxbio and Disc Medicine
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 03 2026
0mins
Should l Buy RGNX?
The Food and Drug Administration review process for accelerated approvals was meant to drugs for rare diseases to pass the approval process, clearing the drugs based on early biological signs instead of waiting years for definitive proof of real-world outcomes, David Wainer of The Wall Street Journal. Now, however, the accelerated approval pathway isn't closed but has become much narrower and harder to predict. Recently, the FDA issued a string of rejections, including Regenxbio's (RGNX) gene therapy for Hunter Syndrome and Disc Medicine's (IRON) treatment for a blood disorder. In some cases, the agency reversed its own guidelines provided to the companies. In 2025, the FDA greenlighted only nine accelerated approvals, down from 20 in 2024. Other companies in the space include: uniQure (QURE), Moderna (MRNA), Replimune (REPL), and Capricor (CAPR).
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGNX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGNX
Wall Street analysts forecast RGNX stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.770
Low
19.00
Averages
29.71
High
45.00
Current: 7.770
Low
19.00
Averages
29.71
High
45.00
About RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address an array of diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). It is developing RGX-121 for the treatment of Mucopolysaccharidosis type II (MPS II), and RGX-111 to treat Mucopolysaccharidosis Type I.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Regenxbio Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Regenxbio for violations of securities laws, concerning securities transactions from February 9, 2022, to January 27, 2026, with a deadline to contact the firm by April 14, 2026.
- False Statements Exposed: The complaint alleges that Regenxbio made false and misleading statements regarding its product candidate RGX-111, concealing negative data about its efficacy and safety, which led to investor losses when the truth emerged.
- Market Reaction: Following the revelation of the true situation regarding RGX-111, investor losses significantly increased, indicating that the company's public statements were materially misleading throughout the class period.
- Legal Consultation Opportunity: The Schall Law Firm offers free legal consultations and encourages affected investors to take action before class certification to ensure their rights are protected.
See More
Notice of REGENXBIO Securities Class Action
- Class Action Deadline: Rosen Law Firm reminds investors who purchased REGENXBIO (NASDAQ:RGNX) securities between February 9, 2022, and January 27, 2026, that they must apply to be lead plaintiff by April 14, 2026, to participate in the class action and seek compensation.
- No Upfront Fees: Investors joining the class action will incur no out-of-pocket fees or costs, as the law firm operates on a contingency fee basis, ensuring that investors' rights are protected without financial risk.
- Case Background: The lawsuit alleges that defendants provided false and misleading information regarding REGENXBIO's RGX-111 gene therapy development, resulting in investor losses when the true facts emerged, negatively impacting the company's reputation and stock price.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, along with being ranked first for the number of settlements in 2017, showcasing its expertise and successful track record in this field.
See More
Faruqi & Faruqi Investigates REGENXBIO Investor Losses
- Legal Investigation Initiated: Faruq & Faruqi LLP is investigating REGENXBIO for potential investor losses incurred between February 9, 2022, and January 27, 2026, indicating possible legal liabilities for the company.
- Investor Rights Reminder: The firm reminds investors that April 14, 2026, is the deadline to apply as lead plaintiff in a federal securities class action, emphasizing the importance of timely action to protect their rights.
- Direct Contact Channels: Partner Josh Wilson has provided direct contact information, encouraging affected investors to call 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss legal options, demonstrating a commitment to client support.
- Potential Legal Consequences: This investigation could lead to a class action lawsuit against REGENXBIO, which, if successful, may negatively impact the company's financial status and stock price, prompting investors to closely monitor developments.
See More
Notice of Class Action Lawsuit for REGENXBIO Securities
- Class Action Deadline: Purchasers of REGENXBIO, Inc. securities are reminded that the deadline to apply as lead plaintiff is April 14, 2026, and failure to act by this date may result in loss of compensation rights.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as attorney fees will be covered through a contingency fee arrangement, thereby reducing financial burdens on investors.
- Case Background: The lawsuit alleges that defendants provided false and misleading information regarding the development of RGX-111 gene therapy, resulting in investor losses when the true facts emerged.
- Law Firm's Strength: The Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and influence in this legal domain.
See More
REGENXBIO Faces Securities Class Action Lawsuit
- FDA Clinical Hold: On January 28, 2026, REGENXBIO faced a clinical hold from the FDA on its RGX-111 gene therapy program after a CNS tumor was discovered, resulting in a $2.40 per share drop, or 17.8%, which significantly impacted investor confidence and market performance.
- Class Action Lawsuit Initiated: A securities class action has been filed in the U.S. District Court for Maryland against REGENXBIO and its executives, alleging misleading statements regarding the safety profile of RGX-111, which may expose investors to substantial losses due to undisclosed safety risks.
- Investor Responsibility Assessment: Institutional investors holding RGNX shares are advised to evaluate their fiduciary obligations and consider actions for recovery, particularly in light of significant losses following the company's stock price decline due to safety concerns.
- Market Reaction Analysis: The lawsuit claims that REGENXBIO's stock was artificially inflated during the class period, and the FDA's clinical hold revealed undisclosed safety risks, leading to a price correction, prompting investors to monitor legal developments and potential recovery opportunities.
See More
Denali Therapeutics Secures FDA Accelerated Approval for Avlayah
- FDA Accelerated Approval: Denali Therapeutics has received FDA accelerated approval for Avlayah, a treatment for Hunter syndrome, significantly enhancing the company's competitive edge in the rare disease market.
- Market Potential Analysis: Analysts highlight Avlayah's strong launch potential, which could drive revenue growth for Denali, attracting a substantial patient base in the coming years and solidifying its position in the biopharmaceutical industry.
- Product Launch Strategy: Denali plans to ensure Avlayah's successful market entry through proactive marketing and partnerships with healthcare institutions, addressing the urgent demand for new therapies and enhancing the company's brand influence.
- Investor Confidence Boost: The FDA approval not only boosts investor confidence in Denali but may also attract additional funding, facilitating further investments in research and market expansion.
See More
Regenxbio Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Regenxbio for violations of securities laws, concerning securities transactions from February 9, 2022, to January 27, 2026, with a deadline to contact the firm by April 14, 2026.
- False Statements Exposed: The complaint alleges that Regenxbio made false and misleading statements regarding its product candidate RGX-111, concealing negative data about its efficacy and safety, which led to investor losses when the truth emerged.
- Market Reaction: Following the revelation of the true situation regarding RGX-111, investor losses significantly increased, indicating that the company's public statements were materially misleading throughout the class period.
- Legal Consultation Opportunity: The Schall Law Firm offers free legal consultations and encourages affected investors to take action before class certification to ensure their rights are protected.
See More
Notice of REGENXBIO Securities Class Action
- Class Action Deadline: Rosen Law Firm reminds investors who purchased REGENXBIO (NASDAQ:RGNX) securities between February 9, 2022, and January 27, 2026, that they must apply to be lead plaintiff by April 14, 2026, to participate in the class action and seek compensation.
- No Upfront Fees: Investors joining the class action will incur no out-of-pocket fees or costs, as the law firm operates on a contingency fee basis, ensuring that investors' rights are protected without financial risk.
- Case Background: The lawsuit alleges that defendants provided false and misleading information regarding REGENXBIO's RGX-111 gene therapy development, resulting in investor losses when the true facts emerged, negatively impacting the company's reputation and stock price.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, along with being ranked first for the number of settlements in 2017, showcasing its expertise and successful track record in this field.
See More
Faruqi & Faruqi Investigates REGENXBIO Investor Losses
- Legal Investigation Initiated: Faruq & Faruqi LLP is investigating REGENXBIO for potential investor losses incurred between February 9, 2022, and January 27, 2026, indicating possible legal liabilities for the company.
- Investor Rights Reminder: The firm reminds investors that April 14, 2026, is the deadline to apply as lead plaintiff in a federal securities class action, emphasizing the importance of timely action to protect their rights.
- Direct Contact Channels: Partner Josh Wilson has provided direct contact information, encouraging affected investors to call 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss legal options, demonstrating a commitment to client support.
- Potential Legal Consequences: This investigation could lead to a class action lawsuit against REGENXBIO, which, if successful, may negatively impact the company's financial status and stock price, prompting investors to closely monitor developments.
See More
Notice of Class Action Lawsuit for REGENXBIO Securities
- Class Action Deadline: Purchasers of REGENXBIO, Inc. securities are reminded that the deadline to apply as lead plaintiff is April 14, 2026, and failure to act by this date may result in loss of compensation rights.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as attorney fees will be covered through a contingency fee arrangement, thereby reducing financial burdens on investors.
- Case Background: The lawsuit alleges that defendants provided false and misleading information regarding the development of RGX-111 gene therapy, resulting in investor losses when the true facts emerged.
- Law Firm's Strength: The Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and influence in this legal domain.
See More
REGENXBIO Faces Securities Class Action Lawsuit
- FDA Clinical Hold: On January 28, 2026, REGENXBIO faced a clinical hold from the FDA on its RGX-111 gene therapy program after a CNS tumor was discovered, resulting in a $2.40 per share drop, or 17.8%, which significantly impacted investor confidence and market performance.
- Class Action Lawsuit Initiated: A securities class action has been filed in the U.S. District Court for Maryland against REGENXBIO and its executives, alleging misleading statements regarding the safety profile of RGX-111, which may expose investors to substantial losses due to undisclosed safety risks.
- Investor Responsibility Assessment: Institutional investors holding RGNX shares are advised to evaluate their fiduciary obligations and consider actions for recovery, particularly in light of significant losses following the company's stock price decline due to safety concerns.
- Market Reaction Analysis: The lawsuit claims that REGENXBIO's stock was artificially inflated during the class period, and the FDA's clinical hold revealed undisclosed safety risks, leading to a price correction, prompting investors to monitor legal developments and potential recovery opportunities.
See More
Denali Therapeutics Secures FDA Accelerated Approval for Avlayah
- FDA Accelerated Approval: Denali Therapeutics has received FDA accelerated approval for Avlayah, a treatment for Hunter syndrome, significantly enhancing the company's competitive edge in the rare disease market.
- Market Potential Analysis: Analysts highlight Avlayah's strong launch potential, which could drive revenue growth for Denali, attracting a substantial patient base in the coming years and solidifying its position in the biopharmaceutical industry.
- Product Launch Strategy: Denali plans to ensure Avlayah's successful market entry through proactive marketing and partnerships with healthcare institutions, addressing the urgent demand for new therapies and enhancing the company's brand influence.
- Investor Confidence Boost: The FDA approval not only boosts investor confidence in Denali but may also attract additional funding, facilitating further investments in research and market expansion.
See More
